%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.Analyst Target
Analyst consensus price target: $8.00.What is BioRestorative Therapies Inc?
develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX · Verdict
Solid reward · moderate risk
BRTX stands out on volatility and growth, but watch the cash flow signal.
Based on 88% data coverage
BRTX · Verdict
What’s working & what to watch
Strengths 4
- Volatility95/100
Top decile vs peers
- Growth81/100
Rev +44.3% CAGR · earnings +2.5%
- Balance sheet77/100
Current ratio 0.84
- Valuation67/100
Above average
Watchouts 2
- Cash flow25/100
-3032% free-cash-flow margin
- Profitability32/100
-3959% net margin · -320% ROE
Model-based scoring. For information only — not financial advice.
What is BioRestorative Therapies Inc?
develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 5.14M.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (61)The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.